Confusional Arousals Market By Cause (Sleep Apnea-Associated, Anxiety-Related, Medication-Induced, Neurological Conditions, Idiopathic), By Diagnosis Method (Polysomnography, Clinical Evaluation, Home Sleep Testing Devices), By Type of Treatment (Pharmacological Treatment, Non-Pharmacological Treatment), By Technology (Wearable Sleep Trackers, EEG-based Monitoring Devices, Smartphone Apps and Digital Platforms, AI-based Sleep Analytics Tools), By End User (Hospitals & Sleep Clinics, Homecare Settings, Specialty Clinics, Research Institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape this market in the coming years?

The Confusional Arousals market accounted for USD 264.5 Million in 2024 and USD 280.9 Million in 2025 is expected to reach USD 512.6 Million by 2035, growing at a CAGR of around 6.2% between 2025 and 2035. The Confusional Arousals Market targets the diagnosis and treatment of a kind of parasomnia, whose feature is the lack of complete sleep, and also leads to disorientation and confused behavior. This situation is quite typical of children and may happen to grown-ups because of sleep disorders, stress, or side effects of medicines.

Market growth is encouraged by increased awareness of sleep health, rising numbers of sleep disorders being diagnosed, and advancements in wearable sleep monitoring technologies. Personalized treatments, use of AI in sleep monitoring, and behavioral therapeutics are also the future areas of innovation.

What do industry experts say about the market trends?

"Confusional arousals are a type of parasomnia where individuals exhibit confusion or disoriented behavior during or following arousals from sleep, typically from deep non-REM sleep. These episodes can involve sitting up in bed, mumbling, or appearing agitated, but the individual usually has no memory of the event the next day."

• Dr. Ronald Chervin, MD, Neurologist

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the market?

Growing global prevalence of sleep disorders across all pediatric and adult age groups.

One of the most significant driving factors in the Confusional Arousals Market is the increasing prevalence of sleep-related conditions. There is an uptick in disorders such as insomnia, sleep apnea, night terrors, and parasomnia disorders like confusional arousals across global populations. This tendency is largely preconditioned by rising exposure to digital screens, poor sleep hygiene, and increasing stress levels. It affects both paediatric and adult age groups, with children being more susceptible to confusional arousals. Recent studies report that 15.2% of adults experienced CAs in the past year, 8.6% had amnesia of the episodes, and 14.8% also had nocturnal wandering, while 70.8% had underlying sleep disorders and 37.4% had mental illnesses such as bipolar or panic disorders.

The demand for clinical diagnosis and treatment is rising as more individuals face disrupted sleep patterns, pushing up referrals and consultations at sleep clinics. Consequently, the demand for polysomnography tests and sleep tracking devices is increasing. Policymakers and stakeholders are also boosting investments in sleep health awareness programs. This growing interest is opening new avenues for pharmaceutical and device manufacturers. As sleep health gains global attention, the Confusional Arousals Market is accelerating. Market players are actively addressing the expanding patient base through specialized treatments and digital solutions, rendering the market highly dynamic and responsive to evolving healthcare needs.

Increasing clinical awareness and timely diagnosis of parasomnias like confusional arousals.

The understanding of parasomnias has also advanced in the past few years, especially when it comes to disorders such as confusional arousals. Now, the healthcare professionals are even poised to differentiate among the different sleep disorders and the subtypes of parasomnias. There is a significance of early detection of confusional arousals to circumvent misdiagnosis and limit the anguish to the patient. Diagnostic tools and protocols upon which to assist in diagnosing are also being progressively introduced in medical institutions and sleep centers. Health organizations have been capitalizing on awareness campaigns to enhance the education of practitioners as well as the general population. Therefore, even more patients turn to it earlier, stimulating the growth of an interest in specific treatment solutions.

The rising incidence of parasomnias reporting and documentation is also contributing to research and innovation of treatment methods. This, in turn, results in the creation of specific behavioral therapies and other types of pharmacological choices. This trend is directly bringing benefits to the Confusional Arousals Market, where more successful diagnosis results in an uptake of the treatment. Moreover, the insurers are starting to realize the added value of covering treatments for sleep disorders in the long term. On the whole, such clinical attention helps the market to grow as it will enable better patient outcomes and adherence to therapy. This aids in putting up a good base towards market expansion in the future.

Limited public awareness in low-income and rural regions about parasomnia-related conditions.

Though medical progress has happened, the low levels of awareness in the underdeveloped states and the rural areas are an influential restriction to the Confusional Arousals Market. The symptoms of parasomnia are not familiar to many patients and their families, who usually confuse it with psychological or behavioral problems. Consequently, they remain underdiagnosed or undertreated even when they are still in their prime. The fact that there is a stigma connected with mental disorders and sleep further aggravates the situation. It is even more difficult in remote areas where there are no trained professionals and sleep diagnostic centers. Medical expenditures are prioritized on more severe or life-threatening ailments in low-income settings. The result of this deprioritization is a shortage of resources in terms of sleep health efforts.

The diagnostic equipment and subsequent treatment are expensive for a great number of people. In the absence of proper infrastructure, early screening and intervention will be an uphill task. This awareness and accessibility gap, thus, presents growth constraints to the Confusional Arousals Market in the two regions. The appropriate way of reducing this disparity is by initiating specific population education and cost-subsidized health plans. The market up to that time will be concentrated on the extended volumes in the urban and high-income areas.

Rapid technological advancements in AI-based diagnostic tools and remote sleep monitoring devices.

The Confusional Arousals Market is being presented with new frontiers by technological innovations. Automatic diagnosis-oriented tools, as well as a remote sleep tracking device, are changing the way NOU is diagnosed and controlled. The use of these integrations spans across clinics as they provide real-time non-clinical collection of the data, making it more convenient and precise. Rings, watches, and wearable headbands are also able to monitor the sleep cycle and identify the irregularities that may indicate parasomnias. This data can be analyzed by AI algorithms in order to raise an alarm about the possible occurrence of confusional arousals, which will make it possible to provide the clinical inspection in due time.

This study method would eliminate the need for expensive in-laboratory sleep studies for a large percentage. It equally supports early intervention, which plays a crucial role, especially in pediatric care and in geriatric care. More engagement of patients is made available through the incorporation of these tools into the digital health ecosystems. With these innovations that the Confusional Arousals Market adopts, it reaches out to more populations that were not well served before. Such developments also enable individual care pathways and forecasting. Even tech giants are spending fortunes in this niche, which encourages more innovation. AI, IoT, and sleep medicine are a revolution that is going to shape the future of the growth of this market.

Rising global demand for non-pharmacological, behavioral, and cognitive sleep therapy solutions.

The rising demand for non-drug-related treatment is leading to major opportunities in the Confusional Arousals Market. Behavioral interventions are favored among many patients, especially children and the elderly, and this is because they do not want to use medication for long-term use. Relaxation methods, cognitive behavioral treatment of insomnia (CBT-I), and relaxation are becoming clinically approved. Such non-pharmacological treatments are usually seen as safer and show fewer side effects. With increased awareness about mental health, increased emphasis on holistic integrative treatment has occurred as well. Lifestyle changes and education about sleep hygiene are moving to the position of first-line treatment or suggestion by healthcare providers.

These therapies are now brought to you by platforms and mobile applications that allow them to be done remotely, and therefore easier to access. Telemedicine is speeding up this change by providing teletherapy with monitoring and therapy sessions from the comfort of one's home. The Confusional Arousals Market is taking advantage of this trend and designing personalized digital medicine and Web-based cognitive courses. Sleep specialists are not readily available in all regions, especially in some parts of the world, and this makes these solutions very attractive. It is expected that the increasing pressure of natural, affordable, and patient-friendly therapy will transform this market substantially. The trend indicates a wider shift towards the preventive and personalized healthcare of sleep.

What are the key market segments in the industry?

Based on the Cause, the Confusional Arousals Market is classified into Sleep Apnea-Associated, Anxiety-Related, Medication-Induced, Neurological Conditions, and Idiopathic. Out of these, sleep apnea-related confusional arousals have the major stakes in the market due to the skyrocketing rate of sleep apnea across the globe, particularly among the adult population and the aged. Sleep apnea also interferes with the sleep architecture by causing arousals partly which may cause parasomnias.

The role of anxiety-related causes and that of medication-related causes also cannot be underestimated, especially amongst adolescents and adults who may be exposed to stress or pharmacological therapies. The related symptoms due to neurological disorders, such as epilepsy or dementia, are also being associated more with parasomnia and thus increasing the market scope. The idiopathic ones are difficult since their etiology is not clear, but there is still a chance of research and innovation.

Based on the Diagnosis Method, the Confusional Arousals Market is classified into Polysomnography, Clinical Evaluation, and Home Sleep Testing Devices. The most common testing modality is Polysomnography (PSG), which is mainly considered to be the gold standard procedure in diagnosing parasomnias and other sleep disorders. PSG gives elaborate information on the brain activity, muscle actions, breathing, as well as the arousal patterns, and is thus imperative in accurate diagnosis.

Clinical evaluations are also becoming preferable because beings are cost-effective and accessible, especially during primary care. The segment of home sleep testing is developing, and it provides convenience and scalability, particularly given the popularity of wearable technology and the growth of remote health monitoring. This will form part of the market diversification to facilitate market growth in diverse care locations.

Which regions are leading the market, and why?

North America Confusional Arousals Market currently holds the largest share, because it has developed healthcare infrastructure, sensitivity to the knowledge of sleep disorders, and the presence of major market players. The area has excellent access to sleep clinics, diagnostic procedures through polysomnography, and special therapies.

Further, coverage of the insurance of sleep-related issues and more focus on mental activity also provide early diagnosis and treatment. The U.S., in particular, spends the most on clinical research and adoptions of digital health, which makes it dominate the market. Yet another factor that enhances sustained demand in this region is the increasing number of the aging population, which is vulnerable to parasomnias.

The Asia-Pacific Confusional Arousals Market is growing at the fastest rate due to the rising interest in sleep hygiene and the spread of medical care. The diagnoses of sleep disorders are on the increase in countries such as China, India, and Japan or as a result of urbanization, stress, and lifestyle changes. As investment in telemedicine and devices to monitor sleep and wear in younger demographics grows, this is, in turn, contributing to the spread of such devices among the younger generation.

Mental health and mental fitness are also being encouraged by the governments, which in a roundabout way is helping the parasomnia treatment market. Comprising a vast number of underserved people and in the presence of advancing diagnostics, the Asia-Pacific is projected to see market growth shortly.  

What does the competitive landscape of the market look like?

The Confusional Arousals Market is relatively fragmented, and the presence of key players includes medications, sleep diagnostics, wearable devices, as well as digital health companies. Because parasomnias occur on a multifactorial basis and overlap with sleep disorders in general, companies have resorted to diverse approaches to meet the direct treatment and assistive diagnostic requirements. The competitive environment is defined by the existence of innovation in the sales of sleep monitoring measures, the growth of behavioral disciplines, and the growth of AI-based diagnostics.

One of the key players in the segment of sleep disorders is Jazz Pharmaceuticals, whose specific items concerning narcolepsy and other parasomnias seem to endow Jazz with active opportunities in this segment. The business model is aimed at broadening the range of indications of the drugs the company discovers, placing bets on clinical trials, as well as working with nationwide neurologists and sleep clinics more closely. They focus on expanding their brand of disorders in the central nervous system (CNS), which will make them an eminent provider of therapeutic solutions for confusional arousals.

Eisai Co., Ltd. remains keen on extending the use of its insomnia pill Dayvigo to deal with other sleep disorders, such as parasomnias. The company uses an effective strategy of physician outreach and education and collaborates with academic institutions in the continuation of research. They have an unmet medical need, which is the provision of non-benzodiazepines to minimize adverse effects that usually accompany sedative hypnotics.

Confusional Arousals Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the industry?

• In May 2024, a wearable neurostimulation device by SleepSync Technologies received CE Mark approval for managing confusional arousals, with early trials indicating a 35% improvement in sleep continuity and reduced nighttime awakenings.
• In April 2024, Stanford Sleep Center partnered with Novo Nordisk to explore metabolic factors in confusional arousals, aiming for new therapeutic targets, with clinical trials expected to commence by early 2025.

Report Coverage:

By Cause

• Sleep Apnea-Associated
• Anxiety-Related
• Medication-Induced
• Neurological Conditions
• Idiopathic

By Diagnosis Method

• Polysomnography
• Clinical Evaluation
• Home Sleep Testing Devices

By Type of Treatment

• Pharmacological Treatment
• Non-Pharmacological Treatment

By Technology

• Wearable Sleep Trackers
• EEG-based Monitoring Devices
• Smartphone Apps and Digital Platforms
• AI-based Sleep Analytics Tools

By End User

• Hospitals & Sleep Clinics
• Homecare Settings
• Specialty Clinics
• Research Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Jazz Pharmaceuticals
• Eisai Co., Ltd.
• Takeda Pharmaceutical Company
• Pfizer Inc.
• Sanofi S.A.
• ResMed Inc.
• Philips Respironics
• Natus Medical Incorporated
• Compumedics Limited
• Somnomedics GmbH
• Fitbit
• Apple Inc.
• Oura Health Ltd.
• Withings
• Eight Sleep

Frequently Asked Questions (FAQs)